Denali Therapeutics Stock Is Sliding After The Bell: Here's Why
Denali Therapeutics Stock Is Sliding After The Bell: Here's Why
Denali is due to report quarterly results again in early November. Analysts expect the company to report a loss of 61 cents per share and revenue of $9.45 million, according to estimates from Benzinga Pro. It's likely that management will provide more details on the Phase 2 study discontinuation leading up to earnings or in the earnings release.Denali Therapeutics Inc (NASDAQ:DNLI) shares are moving lower in Thursday's after-hours session after the company announced that its Phase 2 study of oditrasertib was discontinued.
賽諾菲安萬特公司（納斯達克：DNLI）股票在週四的盤後交易中走低，因爲該公司宣佈其oditrasertib的2期研究被中止。
What Happened: After the market close on Thursday, Denali said strategic partner Sanofi SA (NASDAQ:SNY) informed the company that its K2 Phase 2 study evaluating oditrasertib on serum neurofilament light chain levels in participants with multiple sclerosis was discontinued because it failed to meet the primary and key secondary endpoints.
事件經過：週四收市後，賽諾菲合作伙伴（納斯達克：SNY）告知Denali表示，其K2期評估oditrasertib對患有多發性硬化症的參與者血清神經絲輕鏈水平的2期研究，由於未達到主要和關鍵次要終點而被中止。
In the company's earnings release from August, Denali noted that its Phase 2 study evaluating oditrasertib was fully enrolled. The company did not provide any further updates on the program at the time.
在八月的業績中，Denali指出其評估oditrasertib的2期研究已經完成招募。當時公司沒有提供任何進一步的計劃更新。
Denali is due to report quarterly results again in early November. Analysts expect the company to report a loss of 61 cents per share and revenue of $9.45 million, according to estimates from Benzinga Pro. It's likely that management will provide more details on the Phase 2 study discontinuation leading up to earnings or in the earnings release.
Denali將在十一月初再次報告季度業績。根據Benzinga Pro的估計，分析師預計該公司將報告每股61美分的虧損和945萬美元的營業收入。管理層可能會在業績發佈之前或發佈業績報告時，就2期研究的中止提供更多細節。
Raymond James analyst Danielle Brill reinstated Denali Therapeutics with a Market Perform rating on Thursday morning.
雷蒙德·詹姆斯分析師丹妮爾·布里爾週四早上恢復對Denali Therapeutics的市場表現評級。
Last month, Cantor Fitzgerald reiterated Overweight with a price target of $35, HC Wainwright & Co reiterated Buy with a price target of $90 and BofA Securities maintained a Buy rating and lifted its price target from $25 to $29.
上個月，坎特菲茨傑拉德重申超重，目標價爲35美元，HC Wainwright與Co重申買入，目標價爲90美元，美國銀行證券保持買入評級，並將目標價從25美元上調至29美元。
DNLI Price Action: Denali Therapeutics shares were down 2.29% in after-hours, trading at $25.15 at the time of publication Thursday, according to Benzinga Pro.
DNLI股價走勢：Benzinga Pro報道，Denali Therapeutics的股價週四出版時盤後下跌了2.29％，報25.15美元。
Don't Miss:
• Elon Musk May Unveil Tesla's Robotaxi, But Consumers Respond With 'Ehhh,' New Study Reveals Skepticism, Need For Trust-Building
別錯過：
• 埃隆·馬斯克可能會推出特斯拉的Robotaxi，但消費者的反應是'嗯'，新研究顯示懷疑，需要建立信任
Photo: Pixabay.
圖片來源：Pixabay。
譯文內容由第三人軟體翻譯。
